{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T14:22:41Z","timestamp":1777731761617,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Federal University of S\u00e3o Jo\u00e3o del-Rei, Brazil"},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ejps.2019.05.015","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T13:32:36Z","timestamp":1558618356000},"page":"104937","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Systematic evaluation of the impact of solid-state polymorphism on the bioavailability of thalidomide"],"prefix":"10.1016","volume":"136","author":[{"given":"Guilherme Henrique On\u00f3rio","family":"de Oliveira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Batista","family":"do Nascimento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fl\u00e1vio Martins","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vin\u00edcius Silva","family":"Belo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Jos\u00e9","family":"de Alencar Danda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Lamartine","family":"Soares-Sobrinho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia Lig\u00f3rio","family":"Fialho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo C\u00e9sar Galindo","family":"Bedor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whocely Victor","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2019.05.015_bb0005","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1023\/A:1011052932607","article-title":"Ritonavir crystal forms\u2014an extraordinary example of conformational polymorphism","volume":"18","author":"Bauer","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.05.015_bb0010","series-title":"Polymorphism in Pharmaceutical Solids","author":"Brittain","year":"1999"},{"key":"10.1016\/j.ejps.2019.05.015_bb0015","first-page":"728","article-title":"Contr\u00f4le de dissolution de formes pharmaceutiques orales solides \u00e0 lib\u00e9ration ralentie","volume":"6","author":"Brossard","year":"1990","journal-title":"STP Pharma"},{"key":"10.1016\/j.ejps.2019.05.015_bb0020","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0002-9343(99)00408-8","article-title":"Thalidomide: current and potentional clinical applications","volume":"108","author":"Calabrese","year":"2000","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejps.2019.05.015_bb0025","first-page":"226","article-title":"Investiga\u00e7\u00e3o preliminar avaliando a influ\u00eancia dos processos de compacta\u00e7\u00e3o e tritura\u00e7\u00e3o em rela\u00e7\u00e3o \u00e0s propriedades cristalinas e polim\u00f3rficas da talidomida. L","volume":"28","author":"Carini","year":"2009","journal-title":"Am. J. Pharm."},{"key":"10.1016\/j.ejps.2019.05.015_bb0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijpharm.2008.12.034","article-title":"Solid state evaluation of some thalidomide raw materials","volume":"372","author":"Carini","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2019.05.015_bb0035","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/BF03401909","article-title":"Selection of novel analogs of thalidomide with enhanced tumor necrosis factor a inhibitory activity","volume":"2","author":"Corral","year":"1996","journal-title":"Mol. Med."},{"key":"10.1016\/j.ejps.2019.05.015_bb0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","article-title":"Modeling and comparison of dissolution profiles","volume":"13","author":"Costa","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.05.015_bb0045","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1081\/DDC-120016687","article-title":"Evaluation of mathematical models describing drug release from estradiol transdermal systems","volume":"29","author":"Costa","year":"2003","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2019.05.015_bb0050","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejps.2019.05.015_bb0055","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.05.015_bb0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejps.2013.08.017","article-title":"Effect of experimentally induced hypovolemia on ertapenem tissue distribution using microdialysis in rats","volume":"51","author":"De Castro","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.05.015_bb0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0278-6915(00)00136-8","article-title":"Anatomical and physiological parameters affecting gastrointestinal absorption in human and rats","volume":"39","author":"DeSesso","year":"2001","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ejps.2019.05.015_bb0070","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1742-1241.2001.tb11143.x","article-title":"Thalidomide: 40\u202fyears on","volume":"55","author":"Diggle","year":"2001","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ejps.2019.05.015_bb0075","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/gut.30.4.455","article-title":"Stress effects on gastrointestinal transit time in the rat","volume":"30","author":"Enck","year":"1989","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2019.05.015_bb0080","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1211\/0022357001774660","article-title":"Intravenous formulation of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man","volume":"52","author":"Eriksson","year":"2000","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2019.05.015_bb0085","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s002280100320","article-title":"Clinical pharmacology of thalidomide","volume":"57","author":"Eriksson","year":"2001","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.05.015_bb0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00418-004-0669-x","article-title":"Anti-angiogenic effects of thalidomide: expression of apoptosis-inducible active-caspase-3 in a three-dimensional collagen gel culture of aorta","volume":"122","author":"Fujita","year":"2004","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.ejps.2019.05.015_bb0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/pmj.79.929.127","article-title":"Thalidomide and its derivatives: emerging from the wilderness","volume":"79","author":"Gordon","year":"2003","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ejps.2019.05.015_bb0100","series-title":"Exploring QSAR \u2014 Hydrophobic, Electronic, and Steric Constants., Computer Applications in Chemistry Books","first-page":"108","author":"Hansch","year":"1995"},{"key":"10.1016\/j.ejps.2019.05.015_bb0105","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/bmc.466","article-title":"Concurrent determination of thalidomide in rat blood, brain and bile using multiple microdialysis coupled to liquid chromatography","volume":"19","author":"Huang","year":"2005","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ejps.2019.05.015_bb0110","unstructured":"Iyer, C.G.S., Languillon, J., Ramanujam, K., Tarabini-Castellani, G., Terencio de las Aguas, J., Bechelli, L.M., Uemura, K., Martinez Dominguez, V., Sundaresan, T., 1971. WHO coordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull. World Health Organ. 45, 719\u2013732."},{"key":"10.1016\/j.ejps.2019.05.015_bb0115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ceat.200500397","article-title":"Polymorphism of active pharmaceutical ingredients","volume":"29","author":"Karpinski","year":"2006","journal-title":"Chem. Eng. Technol."},{"key":"10.1016\/j.ejps.2019.05.015_bb0120","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.2042-7158.1975.tb09378.x","article-title":"The concept of dissolution efficiency","volume":"27","author":"Khan","year":"1975","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2019.05.015_bb0125","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1023\/A:1018923714107","article-title":"Does the dose\u2013solubility ratio affect the mean dissolution time of drugs?","volume":"16","author":"L\u00e1nsky","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.05.015_bb0130","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molstruc.2006.11.039","article-title":"Calorimetric determinations and theoretical calculations of polymorphs of thalidomide","volume":"840","author":"Lara-Ochoa","year":"2007","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejps.2019.05.015_bb0135","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0167-5699(99)01531-5","article-title":"Thalidomide as an emerging immunotherapeutic agent","volume":"20","author":"Marriot","year":"1999","journal-title":"Trends Immunol. Today"},{"key":"10.1016\/j.ejps.2019.05.015_bb0140","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.biocel.2007.01.022","article-title":"The thalidomide saga","volume":"39","author":"Melchert","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejps.2019.05.015_bb0145","first-page":"64","article-title":"Mathematical comparison of dissolution profiles","volume":"20","author":"Moore","year":"1996","journal-title":"Pharm. Technol."},{"key":"10.1016\/j.ejps.2019.05.015_bb0150","article-title":"Developmental model for thalidomide action","volume":"400","author":"Neubert","year":"1995","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejps.2019.05.015_bb0155","article-title":"Intuiting mathematical objects using diagrams and kinetigrams","volume":"1","author":"Pais","year":"2001","journal-title":"Journal of online mathematics and its applications (JOMA)"},{"key":"10.1016\/j.ejps.2019.05.015_bb0160","first-page":"204","article-title":"Re-emerging of thalidomide","volume":"35","author":"Patil","year":"2003","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.ejps.2019.05.015_bb0165","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0378-5173(89)90306-2","article-title":"A simple equation for the description of solute release. III. Coupling of diffusion and relaxation","volume":"57","author":"Peppas","year":"1989","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2019.05.015_bb0170","first-page":"2","article-title":"Polymorphism: the phenomenon affecting the performance of drugs","volume":"1","author":"Raza","year":"2014","journal-title":"SOJ Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.05.015_bb0175","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1039\/p29940002063","article-title":"Characterization and crystal structure of two polymorphic forms of racemic thalidomide","volume":"2","author":"Reepmeyer","year":"1994","journal-title":"J. Chem. Soc. Perkin Trans."},{"key":"10.1016\/j.ejps.2019.05.015_bb0180","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1023\/A:1022652004114","article-title":"The mean dissolution time depends on the dose\/solubility ratio","volume":"20","author":"Rinaki","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.05.015_bb0185","first-page":"324","article-title":"The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution","volume":"25","author":"Schumacher","year":"1965","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2019.05.015_bb0190","first-page":"201","article-title":"Disposition of thalidomide in rabbits and rats","volume":"160","author":"Schumacher","year":"1968","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2019.05.015_bb0195","article-title":"Thalidomide: disposition in rhesus monkey and studies of its hydrolysis in tissues of this and other species","volume":"173","author":"Sckumacher","year":"1970","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2019.05.015_bb0200","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/cpt196563303","article-title":"Thalidomide in treatment of lepra reactions","volume":"6","author":"Sheiskin","year":"1965","journal-title":"J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.05.015_bb0205","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijpharm.2013.04.044","article-title":"Mathematical modeling of drug dissolution","volume":"453","author":"Siepmann","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2019.05.015_bb0210","series-title":"Controle de qualidade e avalia\u00e7\u00e3o das propriedades tecnol\u00f3gicas das formas polim\u00f3rficas de talidomida","first-page":"138","author":"Silva","year":"2011"},{"key":"10.1016\/j.ejps.2019.05.015_bb0215","doi-asserted-by":"crossref","first-page":"19","DOI":"10.14227\/DT200113P19","article-title":"Discriminatory dissolution test for tablets containing \u03b1- and \u03b2-thalidomide polymorphs","volume":"20","author":"Silva","year":"2013","journal-title":"Dissolut. Technol."},{"key":"10.1016\/j.ejps.2019.05.015_bb0220","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.addr.2003.10.010","article-title":"Polymorphism in generic drug product development","volume":"5","author":"Sinder","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2019.05.015_bb0225","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejpb.2011.12.016","article-title":"Enhanced kinetic solubility profiles of indomethacin amorphous solid dispersions in poly(2-hydroxyethyl methacrylate) hydrogels","volume":"81","author":"Sun","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2019.05.015_bb0230","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/1099-081X(200001)21:1<33::AID-BDD213>3.0.CO;2-R","article-title":"Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women","volume":"21","author":"Teo","year":"2000","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2019.05.015_bb0235","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/00003088-200443050-00004","article-title":"Clinical pharmacokinetics of thalidomide","volume":"43","author":"Teo","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2019.05.015_bb0240","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/1874091X01105010037","article-title":"Thalidomide analogues suppress lipopolysaccharide-induced synthesis of TNF-\u03b1 and nitrite, an intermediate of nitric oxide, in a cellular model of inflammation","volume":"5","author":"Tweedie","year":"2011","journal-title":"Open Biochem. J."},{"key":"10.1016\/j.ejps.2019.05.015_bb0245","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000197947","article-title":"Transit time changes with the age in the gastrointestinal tract of the rat","volume":"14","author":"Varga","year":"1976","journal-title":"Digestion"},{"key":"10.1016\/j.ejps.2019.05.015_bb0250","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/bdrc.21096","article-title":"Thalidomide-induced teratogenesis: history and mechanisms","volume":"105","author":"Vargesson","year":"2015","journal-title":"Birth Defects Res. C Embryo Today"},{"key":"10.1016\/j.ejps.2019.05.015_bb0255","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4155\/tde.11.19","article-title":"Flip-flop pharmacokinetics \u2014 delivering a reversal of disposition: challenges and opportunities during drug development","volume":"2","author":"Y\u00e1\u00f1ez","year":"2011","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ejps.2019.05.015_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2005.02.041","article-title":"Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat","volume":"39","author":"Yang","year":"2005","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2019.05.015_bb0265","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1258\/002367798780599910","article-title":"Refinement of blood sampling from the sublingual vein of rats","volume":"32","author":"Zeller","year":"1998","journal-title":"Lab. Anim."},{"key":"10.1016\/j.ejps.2019.05.015_bb0270","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1208\/s12248-010-9185-1","article-title":"DDSolver: an Add-In program for modeling and comparison of drug dissolution profiles","volume":"12","author":"Zhang","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2019.05.015_bb0275","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF03226408","article-title":"Transport of thalidomide by the human intestinal Caco-2 monolayers","volume":"30","author":"Zhou","year":"2005","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2019.05.015_bb0280","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00280-005-0087-3","article-title":"Thalidomide does not interact with P-glycoprotein","volume":"57","author":"Zimmermann","year":"2006","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719301927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719301927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T21:04:35Z","timestamp":1694898275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098719301927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":56,"alternative-id":["S0928098719301927"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2019.05.015","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic evaluation of the impact of solid-state polymorphism on the bioavailability of thalidomide","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2019.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104937"}}